|
|
Comparison of safety between two types of enterovirus 71 inactivated vaccine |
HUANG Wei,ZHOU Xiao-hong,XI Sheng-jun,ZHU Jian-hui,GUI Juan-juan,WANG Ting-ting
|
The Center for Disease Control and Prevention of Xiacheng District,Hangzhou,Zhejiang 31003,China |
|
|
Abstract Objective To evaluate the safety of two types of enterovirus 71(EV71)inactivated vaccine(Vero cell vs. Human Diploid cell)after inoculation.Methods Subjects were children vaccinated EV71 vaccine between November 2016 and May 2017 at vaccination clinics in Xiacheng District. According to the type of EV71 vaccine,subjects were divided into the Vero Cell group and the Human Diploid Cell group. The adverse effects were collected after 30 min,3 days and 30 days of injection,respectively.Results A total of 3 158 vaccinated children were observed,with 1 529 in Vero Cell group and 1 629 in Human Diploid Cell group. The rates of adverse effects were 0.59%(9 cases)of Vero cell group and 0.55 %(9cases)of Human Diploid Cell group. All of the adverse effects were systemic reactions such as fever,diarrhea and vomiting. No significant differences were observed between the two groups above in the incidence and severity of adverse effects( P>0.05). The incidence and severity of adverse effects of the first dose were significantly higher than the second dose in two groups(P<0.05).Conclusion EV71 vaccine was safe to vaccinate,and no statistical difference in the adverse effects was found between the two types of vaccine.
|
Published: 26 March 2018
|
|
|
|
|
[1] 涂正波,范骏. 手足口病流行与预防进展[J] . 浙江预防医学,2012,24(7):21-23,26. [2] 吕华坤,缪梓萍,蔡剑,等. 浙江省手足口病流行现况分析[J] . 浙江预防医学,2011,23(1):29-30. [3] 蒋庭魁,王臻,陈慧萍,等. 浙江省2008—2009年手足口病疫情分析[J] . 浙江预防医学,2011,23(2):23-25,27. [4] 王思嘉,易波,许国章,等. 手足口病流行病学研究进展[J] .中国公共卫生管理,2017,33(4):492-496. [5] 浙江省疾病预防控制中心. 浙江省肠道病毒EV71型灭活疫苗预防接种指导意见(试行)[Z] . 2016. [6] 中华人民公共国卫生部. 全国疑似预防接种异常反应监测方案[Z] . 2010. [7] 国家食品药品监督管理局. 预防用疫苗临床试验不良反应分级标准指导原则[Z] . 2005. [8] 叶家楷,李克莉,许涤沙,等. 中国2014年疑似预防接种异常反应信息管理系统监测数据分析[J] . 中国疫苗和免疫,2016,22(2):125-137. [9] 潘雪娇,李倩,戚小华,等. 浙江省2013—2014年疑似预防接种异常反应监测数据分析[J] . 浙江预防医学,2015,27(11):1128-1130. [10] 高波,孙灵英,袁月荣,等. 浙江省宁波市江东区2010—2015年疑似预防接种异常反应监测分析[J] . 中国疫苗和免疫,2017,23(3):322-326. [11] 王亚丽,董锋,王丹,等. 美国疫苗上市后安全性监测给我们的启示[J] . 中国药事,2015,29(9):908-911. [12] 朱月霞,李娜. DTaP -IPV/Hib 五联疫苗接种近期安全性观察[J] . 浙江预防医学,2014,26(5):488-489,534. [13] 唐振,罗海光,谢世林. 贺州市2~59月龄婴幼儿接种b型流感嗜血杆菌结合疫苗安全性观察[J] . 应用预防医学,2014,20(6):359-360,358. [14] 丁瑞华,曾培宇,周剑,等. A群C群脑膜炎球菌多糖疫苗安全性观察[J] . 海峡药学,2015,27(10):97-98. [15] 白云骅,李丽,张军楠,等. 肠道病毒71型灭活疫苗上市后安全性主动监测[J] . 中国公共卫生,2017,33(7):1045-1047. [16] 崔利伟. 2005—2013年深圳市南山区疑似预防接种异常反应监测分析[J] . 现代预防医学,2015,42(16):3022-3024,3048. [17] 叶莹,王长双,马雅婷,等. 河南省2010—2011年疑似预防接种异常反应监测分析[J] . 中国当代儿科杂志,2013,15(6):466-471. |
|
|
|